<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03104088</url>
  </required_header>
  <id_info>
    <org_study_id>Cognition_SPG4</org_study_id>
    <nct_id>NCT03104088</nct_id>
  </id_info>
  <brief_title>Studying Cognition in SPG4</brief_title>
  <official_title>Studying Cognition in SPG4 Compared to Healthy Controls</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Tuebingen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital Tuebingen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Comparing the cognitive levels of patients with SPG4 mutations to healthy controls.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Comparing the cognitive levels of patients with SPG4 mutations to healthy controls by using&#xD;
      the CANTAB® and MoCA.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 10, 2017</start_date>
  <completion_date type="Actual">December 24, 2017</completion_date>
  <primary_completion_date type="Actual">December 24, 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Identifying cognitive affected domains by using CANTAB</measure>
    <time_frame>day 1</time_frame>
    <description>Number of SPG4 patients with affections in the examined cognitive domains by using CANTAB</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">50</enrollment>
  <condition>Cognitive Impairment</condition>
  <condition>Hereditary Spastic Paraplegia</condition>
  <arm_group>
    <arm_group_label>SPG4 patients</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy controls</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>CANTAB</intervention_name>
    <description>CANTAB Cognitive Assessment (tablet based cognitive testing from CAMCOG)</description>
    <arm_group_label>Healthy controls</arm_group_label>
    <arm_group_label>SPG4 patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>MOCA</intervention_name>
    <description>Montreal cognitive assessment (MOCA) in German</description>
    <arm_group_label>Healthy controls</arm_group_label>
    <arm_group_label>SPG4 patients</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Probands will be recruited at the HSP Outpatient Clinic of the Department of Neurology in&#xD;
        Tübingen. Eligible participants are age 18 to 70 years of age. Group 1 include p: patients&#xD;
        with genetically confirmed SPG4 (group 1) and manifest disease with spastic gait disorder.&#xD;
        Group 2 includes age- and sex-matched and healthy controls (spouses, other relatives or&#xD;
        further healthy controls) with an educational level comparable to group 1 (group 2).&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient with SPG4 with known SPAST-Mutation (patient group) or healthy control&#xD;
&#xD;
          -  Age 18 to 70 years&#xD;
&#xD;
          -  Written, informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Lack of ability for a written, informed consent&#xD;
&#xD;
          -  Presence of gait disorder or other neurological condition (for healthy controls)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ludger Schöls, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Tübingen, Center for Neurology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital Tübingen, Center for Neurology</name>
      <address>
        <city>Tubingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>https://doi.org/10.1007/s00415-019-09573-w</url>
    <description>Article Link (DOI)</description>
  </link>
  <results_reference>
    <citation>Rattay TW, Boldt A, Völker M, Wiethoff S, Hengel H, Schüle R, Schöls L. Non-motor symptoms are relevant and possibly treatable in hereditary spastic paraplegia type 4 (SPG4). J Neurol. 2020 Feb;267(2):369-379. doi: 10.1007/s00415-019-09573-w. Epub 2019 Oct 23.</citation>
    <PMID>31646384</PMID>
  </results_reference>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>March 23, 2017</study_first_submitted>
  <study_first_submitted_qc>March 31, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 7, 2017</study_first_posted>
  <last_update_submitted>August 26, 2020</last_update_submitted>
  <last_update_submitted_qc>August 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital Tuebingen</investigator_affiliation>
    <investigator_full_name>Prof. Dr. Ludger Schöls</investigator_full_name>
    <investigator_title>Prinicipal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paraplegia</mesh_term>
    <mesh_term>Spastic Paraplegia, Hereditary</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

